


**Claims**

1. A method for treating angiogenesis or any disease associated with angiogenesis, comprising administering a compound of Formula (I),



Formula (I)


wherein

$R^1$  is independently selected from halo, hydroxy, amino, alkanoylamino,  $-\text{OPO}_3\text{H}_2$ , or  $\text{C}_{1-4}$ alkoxy, wherein the amino group is optionally substituted with an amino acid residue and the hydroxy group is optionally esterified;

X is selected from  $-\text{O}-$ ,  $-\text{S}-$ ,  $-\text{SO}-$ , or  $-\text{SO}_2-$ ;

$R^2$  is selected from hydrogen,  $\text{C}_{1-4}$ alkyl, or  $\text{C}_{1-4}$ alkoxy;

$R^3$  and  $R^4$  are independently selected from hydrogen,  $\text{C}_{1-4}$ alkyl,  $\text{C}_{1-4}$ alkanoyl,  $\text{C}_{1-4}$ alkoxycarbonyl,  $\text{C}_{1-4}$ alkoxycarbonyl $\text{C}_{1-4}$ alkyl,  $\text{C}_{1-4}$ alkoxycarbonylamino, amino, amino $\text{C}_{1-4}$ alkyl, carbamoyl, carbamoyl $\text{C}_{1-4}$ alkyl, cyano, cyano $\text{C}_{1-4}$ alkyl, hydroxy, hydroxy $\text{C}_{1-4}$ alkyl, or a group of Formula (II)




Formula (II)

wherein

$R^6$  is hydrogen or  $\text{C}_{1-4}$ alkyl;

$R^5$  and  $R^7$  are independently selected from hydrogen,  $\text{C}_{1-4}$ alkyl, or a group of Formula (III)



Formula (III)

wherein


Y is selected from —NH—, —O—, or a bond;

Z is selected from —NH—, —O—, —C(O)—, or a bond;

r is an integer from 0 to 4;

t is an integer from 0 to 1;

R<sup>8</sup> is hydrogen, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, aryl, 5- or 6- membered heterocyclyl, 5- or 6-membered heteroaryl, wherein aryl, heteroaryl or heterocyclyl are optionally substituted with C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, or a group of Formula (IV)



Formula (IV)

wherein

n is an integer from 1 to 6, and;

R<sup>9</sup> and R<sup>10</sup> are independently selected from hydrogen, C<sub>1-4</sub>alkyl, or aryl;

p is an integer from 0 to 1; and

q is an integer from 0 to 3;

with the proviso that

- (i) when R<sup>3</sup> is cyano, then R<sup>4</sup> cannot be a group of Formula (II), and
- (ii) when q is 0, R<sup>3</sup> is cyano, and X is —S—, then R<sup>4</sup> is other than amino; or a salt, prodrug, or solvate thereof.

2. A method of claim 1, wherein R<sup>1</sup> is hydroxy, amino, —OPO<sub>3</sub>H<sub>2</sub>, or C<sub>1-4</sub>alkoxy, wherein the amino group is optionally substituted with an amino acid residue and the hydroxy group is optionally esterified.
3. A method of claim 1, wherein X is —O— or —S—.
4. A method of claim 1, wherein R<sup>3</sup> is cyano.
5. A method of claim 1, wherein
  - R<sup>1</sup> is selected from hydroxy, amino, —OPO<sub>3</sub>H<sub>2</sub>, or C<sub>1-4</sub>alkoxy, wherein the amino group is optionally substituted with an amino acid residue;
  - R<sup>2</sup> is hydrogen;
  - X is selected from —O—, —S—, —SO—, or —SO<sub>2</sub>—;

p is 0 or 1;


q is an integer from 1 to 3;

R<sup>3</sup> is selected from hydrogen, cyano, carbamoyl, carbamoylC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkanoyl, or C<sub>1-4</sub>alkoxycarbonyl;

R<sup>4</sup> is selected from hydrogen, cyano, or carbamoyl; and

R<sup>5</sup> is hydrogen or C<sub>1-4</sub>alkyl.

6. A method for treating angiogenesis or any disease associated with angiogenesis, comprising administering a compound of Formula (V),



Formula (V)

wherein


q is from 1 to 3; and

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, X and p are as defined in claim 1,

with the proviso that:

- (i) when R<sup>3</sup> is cyano, then R<sup>4</sup> cannot be a group of Formula (II); and
  - (ii) when (R<sup>1</sup>)<sub>q</sub> is 4-methoxy, 4-amino, or 3,4,5-trimethoxy, p is 0 or 1, R<sup>2</sup> is hydrogen or 5-methoxy, R<sup>3</sup> is hydrogen, cyanomethyl, or 2-aminoethyl, and R<sup>4</sup> is hydrogen or ethoxycarbonyl, then R<sup>5</sup> cannot be hydrogen or methyl;
- or a salt, prodrug or solvate thereof.

7. A compound of Formula (VIId),



Formula (VIId)

wherein

$R^1$  is independently selected from hydroxy, amino, alkanoylamino,  $-\text{OPO}_3\text{H}_2$ , or  $\text{C}_{1-4}$ alkoxy, wherein the amino group is optionally substituted with an amino acid residue and the hydroxy group is optionally esterified;

$X$ ,  $p$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , and  $R^5$  are as defined in claim 1;


$q$  is an integer from 1 to 3;

with the proviso that

- (i) when  $R^3$  is cyano, then  $R^4$  cannot be a group of Formula (II); and
- (ii) when  $(R^1)_q$  is 4-methoxy, 4-amino or 3,4,5-trimethoxy,  $p$  is 0 or 1,  $R^2$  is hydrogen or 5-methoxy,  $R^3$  is hydrogen, cyanomethyl, or 2-aminoethyl, and  $R^4$  is hydrogen or ethoxycarbonyl, then  $R^5$  cannot be hydrogen or methyl;

or a salt, prodrug or solvate thereof.

8. A compound of Formula (VI),



Formula (VI)

wherein

$q$  is from 1 to 3;


$p$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , and  $R^5$  are as defined in claim 7;

with the proviso that

- (i) when  $R^3$  is cyano, then  $R^4$  cannot be a group of Formula (II);
- (ii) when  $(R^1)_q$  is 4-methoxy, 4-amino, or 3,4,5-trimethoxy,  $p$  is 0 or 1,  $R^2$  is hydrogen or 5-methoxy,  $R^3$  is hydrogen, cyanomethyl or 2-aminoethyl, and  $R^4$  is hydrogen or ethoxycarbonyl, then  $R^5$  cannot be hydrogen or methyl;

or a salt, prodrug or solvate thereof.

9. A compound of Formula (VIIC)



Formula (VIIC)

wherein

$X$  is selected from:  $-S-$ ,  $-SO-$ , or  $-SO_2-$ ; and

$p$ ,  $q$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , and  $R^5$  are as defined in claim 7;

with the proviso that

- (i) when  $R^3$  is cyano, then  $R^4$  cannot be a group of Formula (II);
  - (ii) when  $(R^1)_q$  is 4-amino,  $p$  is 0 or 1,  $R^2$  is hydrogen,  $R^3$  is hydrogen, and  $R^4$  is hydrogen or ethoxycarbonyl, then  $R^5$  cannot be hydrogen;
- or a salt, prodrug or solvate thereof.

10. A compound, of claim 7, selected from:

3-cyano-5-phenylsulphanyl-1*H*-indole;

3-cyano-5-phenoxy-1*H*-indole;

3-cyano-5-(4-hydroxyphenoxy)-1*H*-indole; and

2-cyano-5-benzyloxy-1*H*-indole;

1-methyl-3-cyano-5-(4-hydroxy-3,5-dimethoxyphenoxy)-1*H*-indole;

1-methyl-3-cyano-5-(4-phosphonoxy-3,5-dimethoxyphenoxy)-1*H*-indole;

3-cyano-5-(3,4-dimethoxyphenylsulphanyl)-1*H*-indole;

1-methyl-3-cyano-5-(3,4-dimethoxyphenylsulphanyl)-1*H*-indole;


3-cyano-5-(3,4-dimethoxyphenylsulphonyl)-1*H*-indole; and

1-methyl-3-cyano-5-(3,4-dimethoxyphenylsulphonyl)-1*H*-indole;


or salt, prodrug or solvate thereof.

11. A pharmaceutical composition comprising a compound according to any one of Claims 7 to 10 or a pharmaceutically acceptable salt, solvate or prodrug thereof.

12. A process for preparing a compound of claim 1, or salt, solvate or prodrug thereof, comprising
- a) for compounds of Formula (I) wherein X is —O— or —S—, reacting a compound of Formula (A) with a compound of Formula (B),




Formula (A)



Formula (B)


wherein L<sup>1</sup> is a leaving group;

- b) for compounds of Formula (I) in which R<sup>1</sup> is amino, reduction of a compound of Formula (C):




Formula (C);

- c) for compounds of Formula (I) wherein R<sup>5</sup> is C<sub>1-4</sub>alkyl, reacting a compound of Formula (I) wherein R<sup>5</sup> is hydrogen with a suitable alkylhalide;
- d) for compounds of Formula (I) wherein R<sup>1</sup> comprises an amino group substituted with an amino acid residue, reacting a compound of Formula (D) with an amino acid,




Formula (D);

- e) for compounds of Formula (I) in which R<sup>3</sup> is a group of Formula (II) and R<sup>7</sup> is a group of Formula (III), reacting a compounds of Formula (I) in which R<sup>3</sup> is a group of Formula (II) and R<sup>7</sup> is hydrogen with compounds of Formula (E) below, in which L<sup>2</sup> is a leaving group:



Formula (E);

- f) for compounds of Formula (I) in which  $R^4$  is hydrogen, reacting compounds of Formula (I) in which  $R^3$  is hydrogen and  $R^4$  is hydrogen with compounds of  $L^3R^3$  in which  $L^3$  is a leaving group; and
- g) for compounds of Formula (I) in which  $R^1$  is an esterified hydroxyl group, reacting a compound of Formula (F) with an appropriate carboxylic acid or carboxylic acid derivative;



Formula (F)

and thereafter optionally

- i) converting a compound of Formula (I) into another compound of Formula (I);
- ii) removing any protecting groups;
- iii) forming a salt, prodrug or solvate.